The link between cancer and thrombosis has been known for many years. Recently this connection has come to the forefront with increased recognition by healthcare providers and mandates by governing bodies. The results of a thromboembolic event can be catastrophic in a patient with cancer.

Worldwide, there are approximately 500,000 men diagnosed with prostate cancer each year, and in those men prostate cancer is the third most common type of malignancy, surpassed only by cancer of the lung and stomach.1 Other than nonmelanoma skin cancer, prostate cancer is the most commonly diagnosed male cancer in the United States.2 There is disparity in risk of prostate cancer diagnosis between races.

Multiple Myeloma (MM) is a B-cell neoplasm originating from the plasma cell.

At 5 years of follow-up of the VISTA trial, the combination of bortezomib plus melphalan and prednisone (VMP) demonstrated a survival advantage over MP alone as up-front treatment of patients with multiple myeloma who were not transplant candidates. At a median followup of 60.1 months, the absolute difference in overall survival (OS) between the treatment arms was 13 months, according to final results presented at the 53rd Annual Meeting of the American Society of Hematology.

The best strategy for management of low-tumor-burden follicular lymphoma (FL) following response to induction therapy is controversial. The phase 3 RESORT study compared maintenance rituximab therapy versus rituximab retreatment at disease progression, and results suggest that retreatment is the preferred approach. The study was presented at the 53rd Annual Meeting of the American Society of Hematology.

The need to optimize the treatment of patients with cancer while using healthcare resources wisely—in other words, providing “value-based cancer care”—is not a topic of debate, but how to achieve this pressing goal is far from clear. In a panel discussion during the Association for Value-Based Cancer Care’s Second Annual Conference, held in Houston, Texas, strategists from the payer side of the issue discussed the current trends and the challenges they are facing.

At the Association for Value-Based Cancer Care (AVBCC) second annual meeting, Winston Wong, PharmD, expressed concerns that the site of delivery of cancer care affects efforts to rein in costs and provide value in cancer care. Wong expanded on this issue in the following interview.

Why do you believe that the site of delivery of cancer care can impact the attempt to rein in costs of cancer care and provide value?

The inaugural annual conference of the Global Biomarkers Consortium brought together an international panel of oncology experts to explore the rapidly evolving field of biomarker research. Cochairs of the event were Hope S. Rugo, MD, director of Breast Oncology and Clinical Trials Education at the University of California San Francisco, and Rüdiger Hehlmann, MD, PhD, professor of medicine at the University of Heidelberg. Michael Kattan, PhD, Vincent Miller, MD, Edith Perez, MD, and Charles Bennett, MD, PhD, served as session chairs.

Pazopanib, an angiogenesis inhibitor, achieved meaningful responses in about three-quarters of patients with refractory urothelial cancer in preliminary clinical trial results presented at a press briefing during the 2012 Annual Meeting of the American Association for Cancer Research (AACR) in Chicago, Illinois.

Page 1 of 2
Results 1 - 10 of 13